Investment Projects at 2nd International Congress Pharma

Major Investment Projects

PRODUCTION OF MEDICAL PREPARATIONS IN THE FORM OF INJECTIONS AND INFUSIONS

Operator/initiator: ROMPHARM NS

Location: Tashkent, Uzbekistan

Stage: Construction

Dates: Commissioning dates are not yet known

Investment amount: 20 million US dollars An investment project is being realised jointly with a Romanian pharmaceutical company on the construction of a new plant for the production of injectable drugs. The 1st phase of construction is underway. Contractors have not been selected yet.

PRODUCTION OF SUBSTANCES AND MEDICAL PREPARATIONS IN THE FORM OF PILLS, CAPSULES, INJECTIONS (3 PHASES)

Operator/initiator: Cadila MEDICAL PREPARATIONS Uzbekistan LLC

Location: Andijan region, Andijan district, Uzbekistan

Dates: Commissioning: phase 1 – November 2023; phase 2 – October 2024; phase 3 – November 2024

Investment amount: 50 million US dollars

Indian company Cadila MEDICAL PREPARATIONS Ltd. has signed an investment agreement with the Ministry of Investment and Foreign Trade of Uzbekistan on the establishment of the plant on the production of pharmaceutical products on the territory of the Andijan-Pharm FEZ. According to the information provided, it is expected to: attract direct foreign investments in the amount of $50 million in 2020-2025 with the allocation of at least $10 million in 2020-2021 to execute the first phase of the project; generate 400 new job opportunities; organise a modern system of production and quality management of pharmaceutical products that meets international standards. 30 names of medical preparations and medical devices produced by the company will be registered in an accelerated procedure without charging for a registration certificate.

PRODUCTION OF SOLID MEDICAL PREPARATIONS AND CARBAPENEMS

Operator/initiator: Belpharm LLC

Location: Tashkent, Unusabad district, Uzbekistan

Dates: Commissioning is expected in November 2024

Investment amount: 10 million US dollars

As part of the arrangements with the Government of the Republic of Uzbekistan, in September 2018, a decision was made for foreign investors to build a modern pharmaceutical production facility meeting the requirements of the international GMP (Good Manufacturing Practice) standard in Tashkent, Republic of Uzbekistan. Belpharm was established in January 2019 and started the realisation of this project in October 2019. Estimated launch date: production phase 1 – Q2 2023; production phase 2 – Q1 2024.

PRODUCTION AND FRACTIONATION OF IMMUNE CELL ONCOLOGICAL AND STERILE DRUG PRODUCTS, BLOOD PLASMA PROCESSING (PHASE I)

Operator/initiator: Haematech

Location: Innovative R&D pharmaceutical cluster Tashkent Pharma Park

Stage: Requires development and approval of predesign and design documentation

Dates: Feasibility study development period: Q1 2023. Execution period: 2024

Investment amount: Expected project cost: 45 million US dollars

ESTABLISHMENT OF THE TASHKENT PHARMA PARK INNOVATIVE R&D PHARMACEUTICAL CLUSTER (PHASE 1)

Operator/initiator: Agency for the Development of the Pharmaceutical Industry of the Republic of Uzbekistan

Location: Tashkent region, Zangiatinsky district, Uzbekistan

Stage: Construction and commissioning of the administrative buildings of the Pharmaceutical Safety Centre and Development Directorate

Dates: Phase 1 is scheduled to be commissioned in November 2027

Investment amount: 130.2 million US dollars

The project is realised in order to stimulate the comprehensive development of the pharmaceutical industry in the country, including by expanding the range of pharmaceuticals produced, conducting research and development, and training personnel in the field of pharmaceuticals qualified in accordance with international educational standards. Financing of the project is provided by preferential funds of the EDCF Fund of the Eximbank of Korea, the Fund for Reconstruction and Development of the Republic of Uzbekistan, the Fund for Support and Development of the Pharmaceutical Industry and foreign direct investment. The modular structure of the cluster with a total area of 50 hectares involves the establishment of industrial, academic, research, clinical and preclinical sectors. The cluster will host production sites of leading pharmaceutical companies producing innovative medical products, medical devices and equipment, a multi-disciplinary research university and its components, research centres, a state centre of expertise of pharmaceutical products, a data centre and other necessary infrastructure.

PRODUCTION OF MEDICAL PREPARATIONS: ONCOLOGICAL PREPARATIONS

Operator/initiator: HIGHLAND PHARM

Location: Zomin-Pharm FAZ, Zaamin district, Jizzak region, Uzbekistan

Stage: Preparing for construction

Dates: End of 2024

Investment amount: 150 million US dollars

HIGHLAND PHARM plans to build new facilities: it acquires a building and equipment to organise the production of an oncological preparations. In the near future, construction will be commenced in the Zomin-Pharm FEZ.

Request the full list of Investment Projects

    Please note that due to our internal policy we are not entitled to send any materials to personal emails (Yahoo, Yandex, Google, etc.)

    If you have any questions, please contact us:

    +44 207 394 3090 (London)

    Where did you hear about this event?